Selecta Biosciences Inc. [NASDAQ: SELB] stock went on a downward path that fall over -19.02% on Thursday, amounting to a one-week price decrease of less than -19.44%. The company report on April 30, 2021 that Selecta Biosciences Announces Three Presentations at the Upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, announced three upcoming presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held virtually from May 11-14, 2021. These presentations further demonstrate the potential of Selecta’s ImmTOR platform to mitigate AAV immunogenicity and enable redosing of gene therapy treatments for various genetic disorders.
“We are excited to present data on ImmTOR’s potential to address current limitations in the gene therapy field including efficacy, safety and durability at ASGCT,” said Dr. Takashi Kei Kishimoto, Ph.D., chief scientific officer of Selecta. “The results to be presented continue to highlight ImmTOR’s ability to enable redosing of AAV-based gene therapies and prevent the production of AAV-specific neutralizing antibodies (NAbs) in vivo. As many gene therapies will be targeted to pediatric patients, maintaining therapeutic activity is of the utmost importance to families of patients with genetic disorders, a concern that we believe ImmTOR has the potential to solve moving forward.”.
Over the last 12 months, SELB stock rose by 15.38%. The average equity rating for SELB stock is currently 1.90, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $360.45 million, with 107.90 million shares outstanding and 79.85 million shares in the current float. Compared to the average trading volume of 1.46M shares, SELB stock reached a trading volume of 3512356 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Selecta Biosciences Inc. [SELB]:
Mizuho have made an estimate for Selecta Biosciences Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 26, 2021. The new note on the price target was released on October 01, 2020, representing the official price target for Selecta Biosciences Inc. stock. Previously, the target price had yet another raise to $2.50, while Mizuho analysts kept a Neutral rating on SELB stock.
The Average True Range (ATR) for Selecta Biosciences Inc. is set at 0.27, with the Price to Sales ratio for SELB stock in the period of the last 12 months amounting to 21.71. Price to Free Cash Flow for SELB in the course of the last twelve months was 10.57 with Quick ratio for the last quarter at 1.90.
SELB Stock Performance Analysis:
Selecta Biosciences Inc. [SELB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -19.44. With this latest performance, SELB shares dropped by -21.45% in over the last four-week period, additionally plugging by 6.42% over the last 6 months – not to mention a rise of 15.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SELB stock in for the last two-week period is set at 30.70, with the RSI for the last a single of trading hit 24.24, and the three-weeks RSI is set at 35.44 for Selecta Biosciences Inc. [SELB]. The present Moving Average for the last 50 days of trading for this stock 4.15, while it was recorded at 3.75 for the last single week of trading, and 3.28 for the last 200 days.
Insight into Selecta Biosciences Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Selecta Biosciences Inc. [SELB] shares currently have an operating margin of -342.36. Selecta Biosciences Inc.’s Net Margin is presently recorded at -414.99.
Return on Total Capital for SELB is now -252.45, given the latest momentum, and Return on Invested Capital for the company is -554.76. Additionally, SELB Total Debt to Total Capital is recorded at 203.83, with Total Debt to Total Assets ending up at 21.37.
Reflecting on the efficiency of the workforce at the company, Selecta Biosciences Inc. [SELB] managed to generate an average of -$1,601,767 per employee. Receivables Turnover for the company is 2.51 with a Total Asset Turnover recorded at a value of 0.13.Selecta Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 1.90.
SELB Stock EPS
With the latest financial reports released by the company, Selecta Biosciences Inc. posted -0.21/share EPS, while the average EPS was predicted by analysts to be reported at -0.28/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 25.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SELB.
Selecta Biosciences Inc. [SELB] Insider Position Details
There are presently around $160 million, or 53.30% of SELB stock, in the hands of institutional investors. The top three institutional holders of SELB stocks are: BLACKROCK INC. with ownership of 5,474,324, which is approximately 23.986% of the company’s market cap and around 7.20% of the total institutional ownership; VANGUARD GROUP INC, holding 4,999,874 shares of the stock with an approximate value of $15.75 million in SELB stocks shares; and ARTAL GROUP S.A., currently with $14.18 million in SELB stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Selecta Biosciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 63 institutional holders increased their position in Selecta Biosciences Inc. [NASDAQ:SELB] by around 11,765,500 shares. Additionally, 33 investors decreased positions by around 22,551,432 shares, while 11 investors held positions by with 16,446,902 shares. The mentioned changes placed institutional holdings at 50,763,834 shares, according to the latest SEC report filing. SELB stock had 26 new institutional investments in for a total of 3,246,865 shares, while 10 institutional investors sold positions of 7,519,138 shares during the same period.